Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

FRA:ADN1 - DE000A0Z23Q5 - Common Stock

91.2 EUR
+2.6 (+2.93%)
Last: 9/8/2025, 3:16:05 PM
Fundamental Rating

5

Taking everything into account, ADN1 scores 5 out of 10 in our fundamental rating. ADN1 was compared to 71 industry peers in the IT Services industry. ADN1 has an average financial health and profitability rating. ADN1 is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

ADN1 had positive earnings in the past year.
In the past year ADN1 had a positive cash flow from operations.
ADN1 had positive earnings in each of the past 5 years.
ADN1 had a positive operating cash flow in each of the past 5 years.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

ADN1 has a worse Return On Assets (2.34%) than 61.97% of its industry peers.
With a Return On Equity value of 11.09%, ADN1 perfoms like the industry average, outperforming 46.48% of the companies in the same industry.
ADN1 has a worse Return On Invested Capital (5.34%) than 64.79% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ADN1 is significantly below the industry average of 11.13%.
The last Return On Invested Capital (5.34%) for ADN1 is above the 3 year average (3.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.34%
ROE 11.09%
ROIC 5.34%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

ADN1 has a worse Profit Margin (0.96%) than 66.20% of its industry peers.
In the last couple of years the Profit Margin of ADN1 has declined.
With a Operating Margin value of 3.04%, ADN1 is not doing good in the industry: 67.61% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of ADN1 has declined.
With a decent Gross Margin value of 85.66%, ADN1 is doing good in the industry, outperforming 77.46% of the companies in the same industry.
In the last couple of years the Gross Margin of ADN1 has remained more or less at the same level.
Industry RankSector Rank
OM 3.04%
PM (TTM) 0.96%
GM 85.66%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADN1 is destroying value.
Compared to 1 year ago, ADN1 has less shares outstanding
ADN1 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ADN1 has an Altman-Z score of 3.56. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
ADN1 has a better Altman-Z score (3.56) than 71.83% of its industry peers.
The Debt to FCF ratio of ADN1 is 4.22, which is a neutral value as it means it would take ADN1, 4.22 years of fcf income to pay off all of its debts.
ADN1 has a Debt to FCF ratio of 4.22. This is comparable to the rest of the industry: ADN1 outperforms 43.66% of its industry peers.
A Debt/Equity ratio of 0.89 indicates that ADN1 is somewhat dependend on debt financing.
The Debt to Equity ratio of ADN1 (0.89) is worse than 61.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 4.22
Altman-Z 3.56
ROIC/WACC0.52
WACC10.19%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.26 indicates that ADN1 should not have too much problems paying its short term obligations.
ADN1 has a Current ratio (1.26) which is in line with its industry peers.
A Quick Ratio of 1.26 indicates that ADN1 should not have too much problems paying its short term obligations.
ADN1's Quick ratio of 1.26 is fine compared to the rest of the industry. ADN1 outperforms 61.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1204.39% over the past year.
The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
The Revenue has grown by 12.81% in the past year. This is quite good.
ADN1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.60% yearly.
EPS 1Y (TTM)1204.39%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%42.38%
Revenue 1Y (TTM)12.81%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%12.43%

3.2 Future

ADN1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
ADN1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.58% yearly.
EPS Next Y110.51%
EPS Next 2Y77.63%
EPS Next 3Y67.1%
EPS Next 5Y39.88%
Revenue Next Year10.08%
Revenue Next 2Y10.17%
Revenue Next 3Y10.02%
Revenue Next 5Y10.58%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.10, the valuation of ADN1 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ADN1 indicates a slightly more expensive valuation: ADN1 is more expensive than 60.56% of the companies listed in the same industry.
ADN1 is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.06, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 15.85, the valuation of ADN1 can be described as correct.
ADN1's Price/Forward Earnings is on the same level as the industry average.
ADN1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.1
Fwd PE 15.85
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ADN1 is valued a bit cheaper than the industry average as 71.83% of the companies are valued more expensively.
60.56% of the companies in the same industry are more expensive than ADN1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.06
EV/EBITDA 5.67
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

ADN1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADN1's earnings are expected to grow with 67.10% in the coming years.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y77.63%
EPS Next 3Y67.1%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.86%, ADN1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 7.54, ADN1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.86, ADN1 pays less dividend than the S&P500 average, which is at 2.45.
Industry RankSector Rank
Dividend Yield 0.86%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

ADN1 pays out 33.51% of its income as dividend. This is a sustainable payout ratio.
The dividend of ADN1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP33.51%
EPS Next 2Y77.63%
EPS Next 3Y67.1%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (9/8/2025, 3:16:05 PM)

91.2

+2.6 (+2.93%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-12 2025-11-12
Inst Owners16.98%
Inst Owner ChangeN/A
Ins Owners49.36%
Ins Owner ChangeN/A
Market Cap595.54M
Analysts81.54
Price Target127.79 (40.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.86%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP33.51%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.92%
PT rev (3m)0.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.09%
EPS NY rev (3m)-5.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE 30.1
Fwd PE 15.85
P/S 0.29
P/FCF 11.06
P/OCF 7.05
P/B 3.34
P/tB 16.39
EV/EBITDA 5.67
EPS(TTM)3.03
EY3.32%
EPS(NY)5.75
Fwd EY6.31%
FCF(TTM)8.24
FCFY9.04%
OCF(TTM)12.94
OCFY14.19%
SpS315.32
BVpS27.28
TBVpS5.56
PEG (NY)0.27
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.34%
ROE 11.09%
ROCE 12.16%
ROIC 5.34%
ROICexc 5.9%
ROICexgc 8.47%
OM 3.04%
PM (TTM) 0.96%
GM 85.66%
FCFM 2.61%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexcg growth 3Y-20.34%
ROICexcg growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score8
Asset Turnover2.44
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 4.22
Debt/EBITDA 1.19
Cap/Depr 43.51%
Cap/Sales 1.49%
Interest Coverage 4.84
Cash Conversion 63.53%
Profit Quality 272.63%
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 3.56
F-Score8
WACC10.19%
ROIC/WACC0.52
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)1204.39%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%42.38%
EPS Next Y110.51%
EPS Next 2Y77.63%
EPS Next 3Y67.1%
EPS Next 5Y39.88%
Revenue 1Y (TTM)12.81%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%12.43%
Revenue Next Year10.08%
Revenue Next 2Y10.17%
Revenue Next 3Y10.02%
Revenue Next 5Y10.58%
EBIT growth 1Y69.72%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year308.55%
EBIT Next 3Y80.4%
EBIT Next 5Y43.56%
FCF growth 1Y295.38%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y14594.7%
OCF growth 3Y32.14%
OCF growth 5Y37.69%